The Inflammation, Cancer & Immunotherapy (ICI) European Joint Master will aim to introduce students to understand the different pathways in which cancer cells and the immune system interact, to learn how cancer immunotherapies are developed, as well as to learn cutting edge advancement of treatments that are either currently used or are under clinical research to prolong the lives of cancer patients. The course will provide to biomedical or life scientists to acquire an extensive knowledge and key skills relating a deep understanding of inflammation and other immune effector mechanisms, their relation to cancer as well as the fundamental bases of cancer biology and its application to the treatment of cancer. ICI European Joint Master will provide an in-depth understanding of the molecular targets at which the different classes of immunotherapy drugs are aimed, as well as their evolution. Cancer is increasing worldwide, and in a decade, there are expected to be >22M new cases per year. Within this full-time 2 year (120 ECTS) European Joint Master programme the students will be trained to be the next generation of highly qualified interdisciplinary professionals who can be immediately implicated in the design, development and implementation of immunotherapy for cancer, positively impacting on the global burden of cancer. The programme will be delivered by world leaders with internationally renowned research groups at the forefront of inflammation, cancer and immunotherapy research across three leading European universities: University of Murcia (Spain), University of Rouen Normandy (France) and University of Ferrara (Italy). The teachers will also include clinical staff who are involved in the delivery of immunotherapy to patients, as well as in early phases of clinical trials for the study of novel immunotherapy approaches as chimeric antigen receptor T cells. For these goals, ICI will have key non-academic collaborations with hospitals, research centres and industry